Floatz logo

BLARCAMESINE

Parkinson Disease Dementia

Anavex Life Sciences Corp.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Parkinson Disease Dementia cohort.

Asset / SponsorPhaseRating
Rivastigmine
University of Maryland, Baltimore
Phase 4BB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Virginia Commonwealth University
Phase 4BB
BUTYRIN
Prabesh Kanel
Phase 1/2CCC
FOSGONIMETON
LeonaBio
Phase 2CC

Same molecule, other indications

BLARCAMESINE is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
66 / 100
View asset →
Alzheimer diseaseDormant
BB
Indicative ·
64 / 100
View asset →
Parkinson diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →